Welcome to
RBP World!
Drugs target to EEF1A2
| Drug name | Drug type | Disease/phenotype | Mechanism of action(MoA) | Phase | Status | Source |
|---|---|---|---|---|---|---|
| PLITIDEPSIN | Small molecule | COVID-19 | Elongation factor 1-alpha 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PLITIDEPSIN | Small molecule | dedifferentiated liposarcoma | Elongation factor 1-alpha 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| PLITIDEPSIN | Small molecule | COVID-19 | Elongation factor 1-alpha 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | neoplasm | Elongation factor 1-alpha 2 inhibitor | 3.0 | - | ATC |
| PLITIDEPSIN | Small molecule | lymphoma | Elongation factor 1-alpha 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| PLITIDEPSIN | Small molecule | lymphoma | Elongation factor 1-alpha 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | multiple myeloma | Elongation factor 1-alpha 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| PLITIDEPSIN | Small molecule | multiple myeloma | Elongation factor 1-alpha 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | myelofibrosis | Elongation factor 1-alpha 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | leukemia | Elongation factor 1-alpha 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | multiple myeloma | Elongation factor 1-alpha 2 inhibitor | 3.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | multiple myeloma | Elongation factor 1-alpha 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| PLITIDEPSIN | Small molecule | prostate cancer | Elongation factor 1-alpha 2 inhibitor | 2.0 | Terminated | ClinicalTrials |